The IL-15-enhanced CAR T cells were able to expand 10-fold in vitro and 3- to 15-fold in vivo, and in the SCID lymphoma human xenograft model, the iC9/CAR.19/IL-15 T cells demonstrated greater effectiveness, along with better persistence and anti-tumor effects (Hoyos et al., 2010). Here, IL15 is linked to neoplasm.